Overview

• TPG Asia VII SF Pte will offload 1.25 crore shares representing a 6% stake in a block deal valued at Rs 888 crore on June 20
• The sale price of Rs 710 per share reflects a 2.5% discount to the NSE’s last closing price and is being managed by IIFL Capital and Jefferies India
• A 60-day lock-up period will apply to TPG’s remaining equity in Sai Life Sciences after the transaction
• Since its December 2024 listing, Sai Life Sciences’ stock has climbed over 32% and the company forecasts 15–20% annual revenue growth with 28–30% EBITDA margins
• The CRDMO is pursuing Rs 700 crore in capex for global manufacturing expansion, R&D and peptide research to support its growth ambitions